Contact
QR code for the current URL

Press release Box-ID: 55170

Epigenomics AG Geneststr. 5 10829 Berlin, Germany http://www.epigenomics.com/
Contact Hong Thieu +49 30 24345305
Company logo of Epigenomics AG
Epigenomics AG

Epigenomics confirms lead marker for prediction of breast cancer relapse

(PresseBox) (Berlin, Germany and Seattle, WA, USA, )
Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation today announced positive results of a study investigating the prognostic power of its proprietary prognostic PITX2 DNA methylation biomarker in early stage breast cancer.
In addition, the study validated one other prognostic biomarker.

The study again confirmed that the marker is of prognostic value for making treatment decisions in cancer. Previously, Epigenomics has demonstrated a correlation between the presence of low levels of PITX2 gene methylation and low risk of metastasis development and vice versa in prostate cancer patients and in patients with node-negative, hormone-receptor positive breast cancer, a less aggressive form of the cancer. The present study investigated 395 breast cancer patients suffering from lymph node positive cancers, a more aggressive form.

"At present, a lot of breast cancer patients are treated with chemotherapy although they have a low risk of developing metastases,"
Alexander Olek, CEO of Epigenomics said. "However, this group is difficult to identify, so many are treated just for precautionary reasons. Our ultimate goal is to develop a test to find these patients and to provide doctors and patients with the necessary confidence that they don't need to administer chemotherapy."

He added, the data corroborate PITX2 as lead marker in Epigenomics’
panel of markers for the prediction of breast cancer treatment response and relapse. "The benefit of combining PITX2 with other methylation markers to improve prognosis even further will undergo further analysis," Olek said. "Our preliminary results show an even better separation of good versus poor prognosis patient groups when a panel of several markers is used."


Study details
The study was conducted in 395 patients with lymph node positive cancers. All patients were treated with an adjuvant anthracycline-based chemotherapy regimen. Study endpoint was metastasis-free survival. The grouping of patients in a "good" or a "poor" prognosis group was based on a methylation classification function defined in a previous study.
Results: As a single marker, PITX2 methylation identified two-thirds of the patients as belonging to the ”good prognosis" group. In this group, the likelihood of remaining metastasis-free for at least ten years was 62%. In contrast, patients in the “poor prognosis" group had only a 43% chance of remaining metastasis-free for ten years (Kaplan Meier analysis; median follow-up time of 83 months, p< 0.001).


About Breast Cancer Treatment
In breast cancer, post-surgery treatment decisions are currently made by an individualized assessment based on specific risk classes. Most patients receive some form of adjuvant treatment after tumor removal to prevent a relapse of the disease. The decision about an adjuvant treatment is based on nodal status (spread to the axillary lymph glands) and hormone receptor status (response to endocrine therapy). Of all breast cancer patients (annual incidence: 213,000 women in the US and 251,000 women in Europe), about half are lymphnode-negative and hormone receptor positive. In the majority of patients in this group the cancer is effectively treated with surgery and endocrine therapy, without additional cytotoxic chemotherapy. However unfortunately this low-risk patient population is difficult to identify at present. Therefore, most patients will receive additional chemotherapy, even though only a small proportion really requires it.

DNA Methylation
Methylation is a natural epigenetic process in which a methyl group binds to cytosine, one of DNA’s four bases. Methylation is a control mechanism by which cells can switch off genes if their activity is not needed. By measuring the differences in the methylation patterns of healthy and diseased tissue, it is possible to detect changes in gene activity that may trigger diseases such as cancer. Epigenomics has developed an industrial process to read and interpret these methylation patterns.

Epigenomics AG

Die Epigenomics AG ist ein Molekulardiagnostik-Unternehmen mit einem Schwerpunkt auf der Entwicklung neuartiger Produkte für die Krebsdiagnostik. Auf der Basis von DNA-Methylierungs-Biomarkern zielen die Tests von Epigenomics darauf, Krebs bereits im Frühstadium noch vor dem Auftreten erster Symptome zu erkennen und könnten dadurch die durch diese gefürchtete Krankheit verursachte Sterblichkeit verringern.

Die Produktpipeline von Epigenomics umfasst einen klinisch validierten Biomarker für die Früherkennung von Darmkrebs in Blutplasma und weitere firmeneigene DNA-Methylierungs-Biomarker in verschiedenen Entwicklungsstadien für die Früherkennung von Prostata- und Lungenkrebs in Urin- bzw. Blut- und Bronchiallavage-Proben. Epigenomics Septin-9-Biomarker für die Früherkennung von Darmkrebs in einer gewöhnlichen Blutprobe zeigte immer wieder seine hervorragenden Eigenschaften im Rahmen mehrerer klinischer Studien mit insgesamt mehr als 3.500 Probanden.

Für die Entwicklung und Vermarktung als in-vitro-diagnostische Testkits verfolgt Epigenomics eine nicht exklusive Lizenzstrategie, die sich an Partner in der Diagnostikindustrie richtet. Als erster strategischer Partner hat Abbott Molecular Inc. die weltweiten nicht exklusiven IVD-Rechte an Epigenomics Biomarker Septin 9 zur Früherkennung von Darmkrebs einlizenziert. Epigenomics hat sich auch zum Ziel gesetzt, Ärzten und Patienten als Testservice frühzeitig Zugang zu diesen Biomarkern über zentralisierte Referenzlabors zu geben. Als erster Referenzlabor-Partner hat Quest Diagnostics Inc. - führender Anbieter von Diagnostik-Tests, Informationen und Dienstleistungen - die Lizenz für die Vermarktung eines laborentwickelten Tests (LDT) für Septin-9 in den USA erworben.

Epigenomics bietet Partnern aus der Gesundheitsbranche und der biomedizinischen Forschung Zugang zu seinem durch mehr als 150 Patentfamilien geschützten Portfolio aus DNA-Methylierungs-Technologien und -Biomarkern in Form von Forschungsprodukten, Biomarker-Dienstleistungen, IVD-Entwicklungskooperationen und Lizenzabkommen. Das Unternehmen hat seinen Firmensitz in Berlin und ist mit einer 100%igen Tochtergesellschaft in Seattle, WA, USA, vertreten. Weitere Informationen finden sich unter www.epigenomics.com.

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.